Information Provided By:
Fly News Breaks for March 1, 2019
EBS
Mar 1, 2019 | 09:43 EDT
After Emergent BioSolutions announced a new contract award from the U.S. Department of State to supply Trobigard and Reactive Skin Decontamination Lotion kits, Wells Fargo analyst David Maris said he consider it "a very good incremental win." Although the new contract will not likely materially impact 2019 guidance, it is a good tailwind and Maris thinks it is "probably reasonable" for investors to assume a $10M per year run rate over the life of the 10 year deal. He maintains a Market Perform rating and $68 price target on Emergent shares.
News For EBS From the Last 2 Days
EBS
Mar 28, 2024 | 08:22 EDT
Emergent BioSolutions remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN Nasal Spray to help save lives in opioid overdose emergencies. One year after Emergent obtained the historic OTC U.S. FDA approval in March 2023 and seven months since retail launch in August 2023, the availability of NARCAN Nasal Spray in pharmacies, grocery stores and online retailers has helped more people gain access to this life-saving product. Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN Nasal Spray, reducing stigma and further improving access for all Americans. "We're living in a time when one person dies approximately every six minutes from an accidental opioid overdose - prevention and response efforts require an all-hands on deck approach toward lessening this devastating public health crisis," said Joseph Papa, president and CEO of Emergent. "In my first month leading Emergent, and alongside our dedicated colleagues, we continue to advance our mission to protect the public from threats such as the opioid epidemic and am proud of our efforts to help save lives."